Highlights: -More data needed for routine use of TAVI in lower risk patients -First randomised trial of Absorb indicates device has similar one-year clinical outcomes to Xience -Guillaume Cayla: DAPT duration -Leon Neething: Repairing hearts -Profile: Flavio Ribichini
